参考文献/References:
[1]Sung H,Ferlay J,Siegel RL,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[2]Culp MB,Soerjomataram I,Efstathiou JA,et al. Recent global patterns in prostate cancer incidence and mortality rates[J]. Eur Urol,2020,77(1):38-52.
[3]Leong DP,Fradet V,Shayegan B,et al. Cardiovascular risk in men with prostate cancer:insights from the RADICAL PC study[J]. J Urol,2020,203(6):1109-1116.
[4]Sturgeon KM,Deng L,Bluethmann SM,et al. A population-based study of cardiovascular disease mortality risk in US cancer patients[J]. Eur Heart J,2019,40(48):3889-3897.
[5]Ng HS,Koczwara B,Roder D,et al. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy:an Australian population-based cohort study[J]. Prostate Cancer Prostatic Dis,2018,21(3):403-410.
[6]Keating NL,O’Malley AJ,Freedland SJ,et al. Diabetes and cardiovascular disease during androgen deprivation therapy:observational study of veterans with prostate cancer[J]. J Natl Cancer Inst,2010,102(1):39-46.
[7]Bosco C,Bosnyak Z,Malmberg A,et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer:a meta-analysis[J]. Eur Urol,2015,68(3):386-396.
[8]Veccia A,Maines F,Kinspergher S,et al. Cardiovascular toxicities of systemic treatments of prostate cancer[J]. Nat Rev Urol,2017,14(4):230-243.
[9]Gandaglia G,Sun M,Popa I,et al. Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy:a population-based study[J]. Clin Genitourin Cancer,2015,13(3):e123-e130.
[10]d’Ancona FC,Debruyne FM. Endocrine approaches in the therapy of prostate carcinoma[J]. Hum Reprod Update,2005,11(3):309-317.
[11]Scailteux LM,Vincendeau S,Balusson F,et al. Androgen deprivation therapy and cardiovascular risk:no meaningful difference between GnRH antagonist and agonists—A nationwide population-based cohort study based on 2010—2013 French Health Insurance data[J]. Eur J Cancer,2017,77,99-108.
[12]Jespersen CG,N?rgaard M,Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke:a nationwide Danish population-based cohort study[J]. Eur Urol,2014,65(4):704-709.
[13]Lam JS,Leppert JT,Vemulapalli SN,et al. Secondary hormonal therapy for advanced prostate cancer[J]. J Urol,2006,175(1):27-34.
[14]Hedlund PO,Johansson R,Damber JE,et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer:evaluation of cardiovascular events in a randomized trial[J]. Scand J Urol Nephrol,2011,45(5):346-353.
[15]Mikkola A,Aro J,Rannikko S,et al. Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate[J]. Scand J Urol Nephrol,2005,39(4):294-300.
[16]Mikkola AK,Ruutu ML,Aro JL,et al. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer.Efficacy and cardiovascular complications:a 2-year follow-up report of a national,prospective prostatic cancer study.Finnprostate Group[J]. Br J Urol,1998,82(1):63-68.
[17]Levine GN,D’Amico AV,Berger P,et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk:a science advisory from the American Heart Association,American Cancer Society,and American Urological Association:endorsed by the American Society for Radiation Oncology[J]. Circulation,2010,121(6):833-840.
[18]Smith MR,Saad F,Egerdie B,et al. Sarcopenia during androgen-deprivation therapy for prostate cancer[J]. J Clin Oncol,2012,30(26):3271-3276.
[19]Keating NL,O’Malley AJ,Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer[J]. J Clin Oncol,2006,24(27):4448-4456.
[20]Rezaei MM,Rezaei MM,Ghoreifi A,et al. Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy[J]. Can Urol Assoc J,2016,10(9-10):E300-E305.
[21]Gupta D,Lee Chuy K,Yang JC,et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer[J]. J Oncol Pract,2018,14(10):580-587.
[22]Gagliano-Jucá T,Travison TG,Kantoff PW,et al. Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer[J]. J Endocr Soc,2018,2(5):485-496.
[23]Smith MR,Klotz L,Persson BE,Olesen TK,et al. Cardiovascular safety of degarelix:results from a 12-month,comparative,randomized,open label,parallel group phaseⅢtrial in patients with prostate cancer[J]. J Urol,2010,184(6):2313-2319.
[24]Salem JE,Waintraub X,Courtillot C,et al. Hypogonadism as a reversible cause of torsades de pointes in men[J]. Circulation,2018,138(1):110-113.
[25]Barber M,Nguyen LS,Wassermann J,et al. Cardiac arrhythmia considerations of hormone cancer therapies[J]. Cardiovasc Res,2019,115(5):878-894.
[26]Lubart E,Yarovoy A,Gal G,et al. QT interval length in elderly prostatic cancer patients on anti-testosterone treatment[J]. Isr Med Assoc J,2015,17(6):356-359.
[27]Meng F,Zhu S,Zhao J,et al. Stroke related to androgen deprivation therapy for prostate cancer:a meta-analysis and systematic review[J]. BMC Cancer,2016,16:180.
[28]Knutsson A,Hsiung S,Celik S,et al. Treatment with a GnRH receptor agonist,but not the GnRH receptor antagonist degarelix,induces atherosclerotic plaque instability in ApoE(-/-) mice[J]. Sci Rep,2016,6:26220.
[29]Albertsen PC,Klotz L,Tombal B,et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist[J]. Eur Urol,2014,65(3):565-573.
[30]George G,Garmo H,Scailteux LM,et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer:real-world evidence from five databases[J]. Int J Cancer,2021,148(9):2203-2211.
[31]Lopes RD,Higano CS,Slovin SF,et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer:the primary results of the PRONOUNCE randomized trial[J]. Circulation,2021,144(16):1295-1307.
[32]Kulkarni AA,Rubin N,Tholkes A,et al. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients[J]. ESMO Open,2021,6(5):100261.
[33]Omlin A,Pezaro C,Mukherji D,et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms[J]. Eur Urol,2013,64(2):300-306.
[34]Moreira DM,Howard LE,Sourbeer KN,et al. Predicting time from metastasis to overall survival in castration-resistant prostate cancer:results from SEARCH[J]. Clin Genitourin Cancer,2017,15(1):60-66.e2.
[35]Fizazi K,Scher HI,Molina A,et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer:final overall survival analysis of the COU-AA-301 randomised,double-blind,placebo-controlled phase 3 study[J]. Lancet Oncol,2012,13(10):983-992.
[36]Fizazi K,Tran N,Fein L,et al. Abiraterone plus prednisone in metastatic,castration-sensitive prostate cancer[J]. N Engl J Med,2017,377(4):352-360.
[37]Grossebrummel H,Peter T,Mandelkow R,et al. Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways[J]. Int J Oncol,2016,48(2):793-800.
[38]Procopio G,Grassi P,Testa I,et al. Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors[J]. Am J Clin Oncol,2015,38(5):479-482.
[39]Bretagne M,Lebrun-Vignes B,Pariente A,et al. Heart failure and atrial tachyarrhythmia on abiraterone:a pharmacovigilance study[J]. Arch Cardiovasc Dis,2020,113(1):9-21.
[40]Campora S,Campazzi E,Zanardi S,et al. Association of biomarkers with serious cardiac adverse events during abiraterone acetate treatment in castration resistant prostate cancer[J]. Transl Oncol,2016,9(6):600-605.
[41]Rydzewska LHM,Burdett S,Vale CL,et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer:a?systematic review and meta-analysis[J]. Eur J Cancer,2017,84:88-101.
[42]Milliez P,Girerd X,Plouin PF,et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism[J]. J Am Coll Cardiol,2005,45(8):1243-1248.
[43]Beer TM,Armstrong AJ,Rathkopf DE,et al. Enzalutamide in metastatic prostate cancer before chemotherapy[J]. N Engl J Med,2014,371(5):424-433.
[44]Melong N,Steele S,MacDonald M,et al. Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia[J]. Sci Rep,2017,7(1):14698.
[45]Joshua AM,Shore ND,Saad F,et al. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel:expanded access in North America[J]. Prostate,2015,75(8):836-844.
[46]Iacovelli R,Ciccarese C,Bria E,et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer[J]. Clin Genitourin Cancer,2018,16(3):e645-e653.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(1):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(1):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(1):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]